Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 4D Molecular Therapeutic For: Jan 04 Filed by: Viking Global Opportunities GP LLC
-
HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases
-
Form 144 APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Lightmatter Accelerates Growth and Expands Photonic Chip Deployments With $155M in New Funding; Now Valued at $1.2B
-
Ayana Bio Welcomes Industry Veteran Jim Hamilton to its Board of Directors
-
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools
-
Battelle, Revive Environmental to Demonstrate PFAS Technology in Department of Defense Project
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit
-
Form SC 13D/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Pearl Health Releases Annual Report and Survey Findings on the State of Primary Care
-
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
-
DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics
-
Ayana Bio Launches Plant Cell Advantage™ Portfolio with Three New Health and Wellness Ingredients
-
Form SC 13D STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Survey data reveals two-thirds of American adults would eat more and pay more for ultra-processed foods that include more nutritious ingredients
-
Form SC 13G Five9, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
AI startup AlphaSense valued at $2.5 billion after latest funding round
-
AlphaSense Grows to $2.5 Billion Valuation, Securing $150 Million in Series E Funding Led by BOND
-
Battelle Ranked Fifth on Fortune’s 2023 Change the World List for Its PFAS Annihilator® Technology
-
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G RayzeBio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 RayzeBio, Inc. For: Sep 19 Filed by: Viking Global Opportunities Drawdown Portfolio GP LLC
-
Mythic Therapeutics to Present New Preclinical Data on MYTX-011, Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the AACR-NCI-EORTC International Conference on Molecular Targets and C
-
Form 3 RayzeBio, Inc. For: Sep 14 Filed by: VIKING GLOBAL INVESTORS LP
-
Form 3 RayzeBio, Inc. For: Sep 14 Filed by: VIKING GLOBAL INVESTORS LP
-
Walgreens Boots Alliance (WBA) and Pearl Health Announce Strategic Partnership to Advance Value-Based Care Delivery
-
Walgreens and Pearl Health Announce Strategic Partnership to Advance Value-Based Care Delivery
-
Form 4 Inhibrx, Inc. For: Aug 28 Filed by: VIKING GLOBAL INVESTORS LP
-
Inhibrx Inc. (INBX) Announces $200M Financing at $19.35/sh
-
Inhibrx Announces $200 Million Private Placement Financing
-
Form SC 13G VALVOLINE INC Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Jun 30
-
Hedge fund Viking reopens flagship fund after decade -sources
-
Patina teams with Humana to expand reach of convenient, relationship-centered primary care for people with Medicare
-
Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 BridgeBio Pharma, Inc. For: Jul 18 Filed by: VIKING GLOBAL INVESTORS LP

